SensoDetect Sweden is proud to announce major advancements in its China operations following a successful strategic mission to the country from June 26 to July 3. The visit brought together key representatives from both SensoDetect Sweden and its joint venture partner, Beijing Mind Exploration Medical Technology Co., Ltd. (BME), solidifying critical alliances and launching new initiatives aimed at transforming neuropsychiatric diagnostics across China.

Led by Johan Möllerström (Chairman), Wendi Ma (Board Member), and PA Hedin (CEO), SensoDetect's delegation collaborated with BME leadership-Dr. Liu Hai (President) and Zheng Shaoqi (Deputy GM)-engaging with top-tier decision-makers and investors in Beijing, Nantong, and Nanjing.

"We're not just building devices - we're building the future of mental health diagnostics in one of the world's most dynamic healthcare markets," said PA Hedin, CEO of SensoDetect.
"This visit was a breakthrough - deepening high-level partnerships, setting up a production site for our new hardware, and laying the foundation for massive scale."

Strategic partnerships and high-level meetings

The week included pivotal meetings with influential stakeholders, including:

• Li Zhiyong, Vice Chairman & Secretary General, China Association of Medical Equipment
• Executives from SinoPharm, China's largest pharmaceutical distributor
• Leadership from Jiangsu Su-Xi-Tong Industrial Park, with discussions around government incentives
• Several large Chinese investor funds

"There's a shared understanding that early diagnosis is the key to changing outcomes," said Dr. Liu Hai, President of BME. "With this joint venture and our new strategic partners, we're delivering world-class diagnostic innovation to the entire Chinese healthcare system."

New products

In a significant product update, BME will enhance its application to the Chinese NMPA with a redesigned device, BME 1.1, targeting regulatory approval in 2025. This mobile version will be followed by BME 2.0, a stationary unit equipped with Evoked Response Potential (ERP) technology for deeper diagnostics. BME 2.0 is targeting approval in 2026 (see pdf BME 1.1 and 2.0 PR 20250710 for more information).

Clinical studies and early revenue

The joint venture is launching a clinical study involving over 600 ADHD patients across major hospitals in Beijing, Nantong, and Nanjing. Additionally, pilot programs in schools are being rolled out-generating pre-approval revenue while increasing brand exposure and clinical validation.

"The demand for accurate, objective diagnostics for children with ADHD and ASD is overwhelming," said Wendi Ma, Board Member of SensoDetect. "China is ready, and we are bringing the tools."

New production site and base of operations

SensoDetect and BME are in advanced discussions with the regional government of Nantong to establish a new production hub for both BME 1.0 and BME 2.0. Negotiated benefits include:

• Tax incentives and grants
• Land-use rights and mortgage-free loans
• Operational support for scaling manufacturing

With a population of 8 million and proximity to the economic powerhouse of Shanghai, Nantong offers a strategic and scalable manufacturing base.

SinoPharm: Unrivaled distribution reach

BME is forming a strategic partnership with SinoPharm (China National Pharmaceutical Group Co., Ltd.), the country's largest pharmaceutical and healthcare group, and one of the largest medical distributors globally. Highlights include:

• Over 1,700 subsidiaries
• 250,000 employees
• €90 billion in turnover (2023)

"Partnering with SinoPharm gives us instant access to hospitals, clinics, and care centers throughout China - and beyond," said Zheng Shaoqi, Deputy GM of BME.

Market opportunity and revenue potential

China presents one of the world's largest untapped markets for neurodevelopmental diagnostics:

• 200+ million children aged 0-14
• 10-16 million estimated ADHD cases
• 1-2 million estimated ASD cases
• Over 34,000 hospitals nationwide
• Critical need for early detection of ASD (under age 3) and ADHD (at school age)

Revenue Potential
BME 1.1 (mobile):

• Hardware: €5K-€50K/unit
• Assessments: €30-€300/test (80% margin)

BME 2.0 (stationary, ERP-enabled):

• Hardware: €500K-€1M/unit
• Assessments: €60-€600/test (80% margin)

Growth Roadmap

• 2025: NMPA approval for BME 1.1; school rollouts; AI software upgrade
• 2026: Nationwide commercialization; launch of ERP-enabled BME 2.0; AI software update with ERP support

"This is more than expansion - it's transformation," said Chairman Johan Möllerström.
"SensoDetect's vision is becoming reality: scalable, highly profitable, scientifically validated diagnostics in the hands of those who need it most - starting with millions of children across China."